​

Compass Therapeutics (CMPX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CMPX Stock Forecast

Compass Therapeutics (CMPX) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $10.00, with a high of $10.00 and a low of $10.00. This represents a 143.90% increase from the last price of $4.10.

$1 $2 $3 $4 $5 $6 $7 $8 $9 $10 High: $10 Avg: $10 Low: $10 Last Closed Price: $4.1

CMPX Stock Rating

Compass Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 13 Strong Sell Sell Hold Buy Strong Buy

CMPX Price Target Upside V Benchmarks

TypeNameUpside
StockCompass Therapeutics143.90%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts112
Avg Price Target$10.00$10.00$8.00
Last Closing Price$4.10$4.10$4.10
Upside/Downside143.90%143.90%95.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2537---10
Sep, 2537---10
Aug, 2537---10
Jul, 2527---9
Jun, 2527---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 06, 2025Compass Point$10.00$3.70170.27%143.90%
Apr 02, 2025Andrew BerensLeerink Partners$6.00$1.69255.03%46.34%
Sep 16, 2024Aydin HuseynovCompass Point$5.00$1.65203.03%21.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 13, 2024JefferiesBuyBuyhold
Apr 26, 2022Zacks Investment ResearchSelldowngrade

Financial Forecast

EPS Forecast

$-15 $-6 $3 $12 $21 $30 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.33-----
Avg Forecast$-0.33$-0.35$-0.40$-0.45$-0.03$0.78
High Forecast$-0.31$-0.32$-0.26$0.34$26.30$1.13
Low Forecast$-0.40$-0.40$-0.63$-1.28$-13.50$0.44
Surprise %------

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$907.14K$6.22M$61.18M$180.20M$364.77M
High Forecast-$927.76K$8.33M$61.18M$184.89M$488.96M
Low Forecast-$876.22K$4.10M$61.18M$175.51M$240.57M
Surprise %------

Net Income Forecast

$-2B $-900M $200M $1B $2B $4B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.49M-----
Avg Forecast$-42.49M$-47.76M$-61.25M$-65.80M$788.86K$99.59M
High Forecast$-39.72M$-40.65M$-32.88M$42.75M$3.34B$143.67M
Low Forecast$-51.25M$-50.81M$-79.86M$-162.72M$-1.71B$55.51M
Surprise %------

CMPX Forecast FAQ

Is Compass Therapeutics stock a buy?

Compass Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Compass Therapeutics is a favorable investment for most analysts.

What is Compass Therapeutics's price target?

Compass Therapeutics's price target, set by 13 Wall Street analysts, averages $10 over the next 12 months. The price target range spans from $10 at the low end to $10 at the high end, suggesting a potential 143.90% change from the previous closing price of $4.1.

How does Compass Therapeutics stock forecast compare to its benchmarks?

Compass Therapeutics's stock forecast shows a 143.90% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Compass Therapeutics over the past three months?

  • October 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Compass Therapeutics’s EPS forecast?

Compass Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.35, marking a 6.06% increase from the reported $-0.33 in 2023. Estimates for the following years are $-0.4 in 2025, $-0.45 in 2026, $-0.03 in 2027, and $0.78 in 2028.

What is Compass Therapeutics’s revenue forecast?

Compass Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $907.14K, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $6.22M, followed by $61.18M for 2026, $180.2M for 2027, and $364.77M for 2028.

What is Compass Therapeutics’s net income forecast?

Compass Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-47.757M, representing an 12.39% increase from the reported $-42.494M in 2023. Projections indicate $-61.246M in 2025, $-65.804M in 2026, $788.86K in 2027, and $99.59M in 2028.